Home > Boards > US Listed > Biotechs > Chelsea Therapeutics International Ltd. (CHTP)

Too low ball offer to take!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
onemodolar Member Profile
 
Followed By 2
Posts 91
Boards Moderated 0
Alias Born 12/02/13
160x600 placeholder
onemodolar   Thursday, 05/08/14 11:50:14 AM
Re: None
Post # of 3033 
Too low ball offer to take!
$6.44 is way too low considering intra day high of $6.83.
There should be no CVR nonsense!

I am curious what the trigger is to collect CVR of $1.50/sh in 2018.
Analysts estimates ranges from $400 mil to $700 mil.
Do the math - $400 X 5 = $2 billion
The BOD takes offer for $683 mil with a guarantee of trigger sales in Year 2015 through 2017 and they are confident Northera sales will surpass the trigger. If BOD is so positive about Northera Marker, why not GIA?

It is hard to justify 70% discount on already approved Northera despite no established marketing resources.

It's gotta be minimum $8/sh CASH or I would prefer GIA.
I wonder Baker Brothers agree on this term.
I am going to join Proxy fight against this deal.
All IMO.
GLTA

P.S. I greatly appreciate hard work and all the success current management achieved for the shareholders.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences